Collaboration - May 10, 2021
Glooko collaborates with Eli Lilly
Glooko has announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly’s connected insulin pen solutions. The technology collaboration will ease insulin management for people with diabetes and their healthcare providers in markets outside the U.S., via integration of Lilly’s Tempo Pen and Tempo Smart Button (currently in late-stage […]
Collaboration - December 16, 2016
AstraZeneca, Lilly to develop treatment for Alzheimer’s
AstraZeneca and Eli Lilly and Company have signed a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD). This agreement builds on the existing collaboration related to AZD3293, a BACE inhibitor in two pivotal Phase III […]
Agreement - September 17, 2014
AstraZeneca and Eli Lilly enter agreement
The two companies have announced an alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease. The aim is to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer’s disease. Lilly will lead clinical development, working with researchers from AstraZeneca’s Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible […]
Drug Development Pharma - May 26, 2014
EU approves Eli Lilly-Boehringer diabetes drug
The European Commission has granted marketing authorization for Jardiance (empagliflozin) tablets. It is a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of type 2 diabetes mellitus (T2D) to improve glycemic control in adults in Europe. The European Commission approved JARDIANCE 10 and 25 mg once daily tablets for use when diet and exercise […]
